<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53601">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01844531</url>
  </required_header>
  <id_info>
    <org_study_id>1276.6</org_study_id>
    <secondary_id>2012-000082-20</secondary_id>
    <nct_id>NCT01844531</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets</brief_title>
  <official_title>Bioequivalence of Empagliflozin/Metformin (500 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open-label, Randomised, Single-dose, Four-way Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to establish bioequivalence of two fixed dose
      combination (FDC) tablets (containing medium dose empagliflozin/500 mg metformin [Test 1]
      and low dose empagliflozin/500 mg metformin [Test 2]) and of the single tablets (medium dose
      empagliflozin tablets + Glucophage速 500 mg tablet [Reference 1] and low dose empagliflozin
      tablet + Glucophage速 500 mg tablet [Reference 2]) when administered together after a high
      fat, high caloric meal.

      The assessment of safety and tolerability will be an additional objective of this trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 72 hours after drug intake</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 72 hours after drug intake</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)</measure>
    <time_frame>up to 72 hours after drug intake</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>FDC empagliflozin dose 1 and metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fix dose combination tablet after intake of a high fat, high caloric meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin dose 1 + metformin tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single tablets after intake of a high fat, high caloric meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDC empagliflozin dose 2 and metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fix dose combination tablet after intake of a high fat, high caloric meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin dose 2 + metformin tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single tablets after intake of a high fat, high caloric meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin</intervention_name>
    <description>single tablet empagliflozin</description>
    <arm_group_label>empagliflozin dose 1 + metformin tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin (Glucophage速)</intervention_name>
    <description>single tablet metformin</description>
    <arm_group_label>empagliflozin dose 1 + metformin tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin (Glucophage速)</intervention_name>
    <description>single tablet metformin</description>
    <arm_group_label>empagliflozin dose 2 + metformin tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin</intervention_name>
    <description>single tablet empagliflozin</description>
    <arm_group_label>empagliflozin dose 2 + metformin tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin and metformin</intervention_name>
    <description>FDC tablet empagliflozin and metformin</description>
    <arm_group_label>FDC empagliflozin dose 1 and metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin and metformin</intervention_name>
    <description>FDC tablet empagliflozin and metformin</description>
    <arm_group_label>FDC empagliflozin dose 2 and metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy male and female subjects

          2. Subjects must be able to understand and comply with study requirements

          3. Age 18 to 50 years

          4. Body mass index (BMI) 18.5 to 29.9 kg/m2

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1276.6.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 11, 2013</lastchanged_date>
  <firstreceived_date>April 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
